5月20日主题复盘 | 谷子经济、宠物经济大涨，医药表现不俗

Market Overview - The market experienced a rebound with the North Stock 50 and Micro Stock Index reaching historical highs. The pet economy concept saw a collective surge, with companies like Yuanfei Pet and Yiyi Co. hitting the daily limit. The IP economy also strengthened, with companies such as Shifeng Culture and Haole Co. reaching the limit. Pharmaceutical stocks rose, with SanSheng Guojian and Huahai Pharmaceutical hitting the limit. M&A and restructuring stocks remained strong, while the shipping sector faced adjustments, with companies like Phoenix Shipping and Lianyungang hitting the limit down. Over 3,800 stocks in Shanghai, Shenzhen, and Beijing rose, with a total transaction volume of 1.21 trillion [1]. Hot Topics IP Economy / Guzi Economy - The Guzi economy sector saw significant gains, with stocks like Guobo Co., Chuangyuan Co., and Jinghua Laser hitting the daily limit. The catalyst for this surge was the historical high of Pop Mart's stock price in Hong Kong, with a market value approaching 300 billion [4][5]. - According to iiMedia Consulting, the market size of China's Guzi economy is expected to reach 168.9 billion in 2024, a year-on-year increase of 41%, and is projected to exceed 200 billion by 2025. Compared to the US and Japan, the conversion rate of domestic IP in film and television is relatively low, indicating significant potential for growth in China's Guzi industry [5][6]. Pet Economy - The pet economy sector exploded again, with Yuanfei Pet and Tianyuan Pet achieving two consecutive daily limits, and Yiyi Co. hitting the limit. Other companies like Lusi Co., Ruipu Biological, and Petty Co. also saw significant increases. The catalyst for this growth is the upcoming 2025 Shanghai Pet Expo, which is expected to break historical records in terms of participants and transaction amounts [7][8]. - According to iiMedia Consulting, the domestic pet industry is projected to reach 811.4 billion this year, with expectations to surpass 1 trillion in two years [9]. Pharmaceutical Sector - The pharmaceutical sector saw a significant rise, with SanSheng Guojian hitting the daily limit and other companies like Huahai Pharmaceutical and Weiming Pharmaceutical also reaching the limit. A key catalyst was SanSheng Pharmaceutical's announcement of a licensing agreement with Pfizer for its PD-1/VEGF dual-specific antibody SSGJ-707, which includes a $1.25 billion upfront payment and potential milestone payments of up to $4.8 billion [10][11]. - The agreement marks a record for the amount of foreign licensing for Chinese innovative drugs in recent years, indicating an escalation in competition in the global PD-1/VEGF dual antibody market [10][11]. Other Active Sectors - Besides the highlighted sectors, asset restructuring, consumer goods, and domestic chips are also active. In contrast, the chemical, shipping, and military sectors experienced the most significant declines [12].